BEIJING, December 16, 2024--(BUSINESS WIRE)--Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today kicked off the enrollment ...
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, kicked off the enrollment for a phase ? clinical trial on a vaccine candidate to prevent hand foot and mouth disease ...
A new vaccine against enterovirus 71 (EV71) can effectively prevent hand, foot, and mouth disease (HFMD) as well as hospitalizations for severe HFMD and EV71-associated disease, according to a phase 3 ...
A novel mechanism for EV71 entry mediated by its receptor SCARB2 has been reported by scientists. These findings make a significant conceptual advance in the understanding of non-enveloped virus entry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results